Abstract
In LIBERTY ASTHMA QUEST (NCT02414854), add-on dupilumab vs placebo reduced severe asthma exacerbations (AER) in patients with uncontrolled, moderate-to-severe asthma. Treatment effects were greater in patients with elevated type 2 (T2) biomarkers (blood eosinophils ≥150cells/μL or FeNO ≥25ppb). The TRAVERSE (NCT02134028) open-label extension study evaluated long-term safety and tolerability of add-on dupilumab in patients who participated in a previous dupilumab asthma study. Long-term dupilumab efficacy by baseline T2 biomarker quadrant was evaluated in QUEST patients continuing in TRAVERSE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
